Cadrenal Therapeutics (NASDAQ:CVKD) CEO Sells 9,029 Shares

Posted by Brian Himes on Jun 26th, 2026

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD – Get Free Report) CEO Quang Pham sold 9,029 shares of the stock in a transaction on Friday, June 26th. The shares were sold at an average price of $3.05, for a total value of $27,538.45. Following the completion of the transaction, the chief executive officer owned 105,989 shares of the company’s stock, valued at $323,266.45. This trade represents a 7.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cadrenal Therapeutics Price Performance

Shares of NASDAQ CVKD traded up $0.19 during mid-day trading on Friday, reaching $3.05. The company had a trading volume of 51,501 shares, compared to its average volume of 74,882. The stock has a fifty day moving average of $4.76 and a two-hundred day moving average of $6.24. Cadrenal Therapeutics, Inc. has a 12-month low of $2.55 and a 12-month high of $14.64.

Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.51) by $0.47. Equities research analysts predict that Cadrenal Therapeutics, Inc. will post -5.52 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. HC Wainwright lowered their price objective on Cadrenal Therapeutics from $32.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Wall Street Zen raised Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $13.00.

Check Out Our Latest Analysis on CVKD

Hedge Funds Weigh In On Cadrenal Therapeutics

Large investors have recently made changes to their positions in the business. DRW Securities LLC acquired a new stake in Cadrenal Therapeutics in the 4th quarter valued at approximately $171,000. Geode Capital Management LLC boosted its position in shares of Cadrenal Therapeutics by 14.3% in the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after acquiring an additional 1,818 shares during the period. JPMorgan Chase & Co. bought a new stake in shares of Cadrenal Therapeutics in the third quarter valued at approximately $103,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Cadrenal Therapeutics in the third quarter worth $274,000. Institutional investors and hedge funds own 7.92% of the company’s stock.

About Cadrenal Therapeutics

(Get Free Report)

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.